micro-community-banner
 
  • Saved

FDA Places Clinical Hold on Allogene CAR-T Cancer Trials

FDA Places Clinical Hold on Allogene CAR-T Cancer Trials

Source : https://www.genengnews.com/news/fda-places-clinical-hold-on-allogene-car-t-cancer-trials/

Allogene Therapeutics saw its shares fall more than 40% in early trading Friday after acknowledging that the FDA had placed a clinical hold on its trials evaluating its allogeneic CAR...

  • Saved
Waldenstrom Macroglobulinemia patient with incomplete response – next steps?

50 year old male with unclear B cell lymphoma, watched for 3-4 years. When presented to care, had diffuse low volume adenopathy. Biopsy with molecular diagnostics was repeated, which showed Waldenstrom Macroglobulinemia (WM) based on a NMYD88 mutation. Patient was observed for 3-4 months with increasing peripheral edema. Patient was restaged and found minimal FDG avid nodes in systemic nodes, bone marrow with WM. Patient was started on RBendamustine (other options were ibrutinib vs others). Patient had incomplete response to RBenda. Renal biopsy was performed because of hypoalbumineia and renal amyloid was identified.

How would you have managed this patient and his treatment regimen(s)? What would you recommend as next steps?

  • 4yr
    I think a BTK inhibitor, such as Imbruvica or Calquence, would be reasonable.
  • 4yr
    What are your thoughts on BTK inhibitors?

Show More Comments

  • Saved

Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: a systematic review and meta-analysis - PubMed

Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: a systematic review and meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34656744/

CNS prophylaxis is commonly used in Diffuse Large B-Cell Lymphoma (DLBCL) patients with risk features for CNS relapse. This systematic review and meta-analysis compares CNS relapse rates with and without...

  • Saved

Current and emerging treatment options in primary mediastinal B-cell lymphoma - PubMed

Current and emerging treatment options in primary mediastinal B-cell lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34659697/

Previously considered a subtype of diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) is now recognized by the World Health Organization as an independent entity. PMBCL has clinicopathologic...

  • Saved

Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature - PubMed

Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34659910/

Post-transplant lymphoproliferative disorders (PTLD) are among the most serious complications after solid organ transplantation (SOT). Monomorphic diffuse large B-cell lymphoma (DLBCL) is the most common subtype of PTLD. Historically, outcomes...